Tag: Drugs
Search News
In conversation with Professor Marco Gerlinger
20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more
Rewiring the biology of leukaemia cells to reverse drug resistance
20th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.
Read more
Clinical study to investigate new personalised treatment for ovarian cancer
14th March 2022
Dr Michelle Lockley from Barts Cancer Institute at Queen Mary University of London has received funding from Barts Charity and the Anticancer Fund to investigate a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy.
Read more
Immunotherapy significantly reduces recurrence in aggressive breast cancer
10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more
Investigating new strategies to target lung cancer
6th December 2021
Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.
Read more
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more